Nothing Special   »   [go: up one dir, main page]

KR890003734A - 신규한 nf-1616-904의 피라진옥사이드 화합물 및 이를 함유하는 약학 조성물 - Google Patents

신규한 nf-1616-904의 피라진옥사이드 화합물 및 이를 함유하는 약학 조성물 Download PDF

Info

Publication number
KR890003734A
KR890003734A KR1019880010242A KR880010242A KR890003734A KR 890003734 A KR890003734 A KR 890003734A KR 1019880010242 A KR1019880010242 A KR 1019880010242A KR 880010242 A KR880010242 A KR 880010242A KR 890003734 A KR890003734 A KR 890003734A
Authority
KR
South Korea
Prior art keywords
pyrazine oxide
oxide compound
formula
pharmaceutical compositions
compositions containing
Prior art date
Application number
KR1019880010242A
Other languages
English (en)
Other versions
KR960005150B1 (ko
Inventor
요시마사 나까노
미찌하루 스가와라
세쯔요시 우에쯔끼
다께또시 이자와
도모유끼 가와구찌
아끼라 와다
Original Assignee
오오쓰까 아끼히꼬
오오쓰까이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오오쓰까 아끼히꼬, 오오쓰까이야꾸 가부시끼가이샤 filed Critical 오오쓰까 아끼히꼬
Publication of KR890003734A publication Critical patent/KR890003734A/ko
Application granted granted Critical
Publication of KR960005150B1 publication Critical patent/KR960005150B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

신규한 NF-1616-904의 피라진옥사이드 화합물 및 이를 함유하는 약학 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명의 신규한 NF-1616-902의 중간체 화합물으1H-NMR스펙트럼도를 나타낸 도이다. 제2도는 상기 중간체 화합물의13C-NNR스펙트럼도를 나타낸 도이다. 제3도는 상기 중간체 화합물의 IR-흡수 스펙트럼도를 나타낸 도이다.

Claims (5)

  1. 하기 구조식(1)의 NF-1616-904의 피라진옥사이드 화합물.
  2. 티엘라비아(Thielavia)속에 속하는 미생물의 배양 배지로부터 분리된 NF-1616-902의 중간체 화합물을 가수분해시켜,제1항에 따른 구조식(Ⅰ)의 NF-1616-904의 피라진옥사이드 화합물을 제조하는 방법.
  3. 제2항에 있어서, 티엘라비아속에 속하는 미생물이 티엘라비아 미노르(Thielavia minor) OFR-1561(FERM-1908)인 방법.
  4. 과산화물 라디칼에 의해 유발된 질병을 예방 및 치료 하기 위한 것으로서, 제1항에 따른 구조식(1)의 NF-1616-904의 피라진옥사이드 화합물을 활성 성분으로 함유하는 약학 조성물.
  5. 신염을 예방 및 치료하기 위한 것으로서, 제1항에 따른 구조식(1)의 NF-1616-904의 피라진옥사이드 화합물을 활성 성분으로 함유하는 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880010242A 1987-08-11 1988-08-11 신규한 nf-1616-904의 피라진옥사이드 화합물 및 이를 함유하는 약학 조성물 KR960005150B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20153787 1987-08-11
JP62-201537 1987-08-11

Publications (2)

Publication Number Publication Date
KR890003734A true KR890003734A (ko) 1989-04-17
KR960005150B1 KR960005150B1 (ko) 1996-04-22

Family

ID=16442692

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880010242A KR960005150B1 (ko) 1987-08-11 1988-08-11 신규한 nf-1616-904의 피라진옥사이드 화합물 및 이를 함유하는 약학 조성물

Country Status (9)

Country Link
US (1) US5021419A (ko)
EP (1) EP0303250B1 (ko)
JP (1) JPH01131177A (ko)
KR (1) KR960005150B1 (ko)
CN (1) CN1028655C (ko)
DE (1) DE3880231T2 (ko)
DK (1) DK170617B1 (ko)
ES (1) ES2054748T3 (ko)
MX (1) MX9202936A (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238938A (en) * 1989-02-10 1993-08-24 Otsuka Pharmaceutical Co., Ltd. Indole derivatives
WO1990009380A1 (en) 1989-02-10 1990-08-23 Otsuka Pharmaceutical Co., Ltd. Indole derivatives, preparation thereof, and drug for preventing and treating nephritis containing same
CN1038586C (zh) * 1991-05-01 1998-06-03 大制药株式会社 吡嗪衍生物的制备方法
SE529897C2 (sv) 2006-03-27 2007-12-27 Rottneros Ab Formpressat tråg

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8427735D0 (en) * 1984-11-02 1984-12-12 Fujisawa Pharmaceutical Co Piperazine compound

Also Published As

Publication number Publication date
ES2054748T3 (es) 1994-08-16
DK446388A (da) 1989-02-12
JPH01131177A (ja) 1989-05-24
EP0303250A2 (en) 1989-02-15
DK170617B1 (da) 1995-11-13
EP0303250B1 (en) 1993-04-14
CN1032031A (zh) 1989-03-29
EP0303250A3 (en) 1990-07-11
DE3880231T2 (de) 1993-10-07
CN1028655C (zh) 1995-05-31
KR960005150B1 (ko) 1996-04-22
MX9202936A (es) 1992-06-30
US5021419A (en) 1991-06-04
DK446388D0 (da) 1988-08-10
JPH0557273B2 (ko) 1993-08-23
DE3880231D1 (de) 1993-05-19

Similar Documents

Publication Publication Date Title
YU48913B (sh) Postupak za dobijanje novih smeša na bazi derivata iz klase taksana
ES2044836T3 (es) Derivado de la piperidina, su utilizacion y compuesto farmaceutico que lo contiene.
YU54896A (sh) (methilsulfonil)fenil-2-(5h)-furanoni kao cox-2 inhibitori
ATE16488T1 (de) M-4- und isom-4-derivate, ihre herstellung und diese enthaltende zusammensetzungen.
FR2374307A1 (fr) Derives de la 1,4-dihydropyridine, leur procede d'obtention et composition pharmaceutique les contenant
AU6319480A (en) 2-hydroxyalkyl-3,4,5-trihydroxypiperidines
KR890009962A (ko) 매뉴마이신 유도체, 이의 제조방법 및 용도
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
KR890003734A (ko) 신규한 nf-1616-904의 피라진옥사이드 화합물 및 이를 함유하는 약학 조성물
CA2107485A1 (fr) Nouveaux derives d'ellipticine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0378825A3 (fr) Esters alicycliques et leur utilisation à titre d'ingrédients parfumants
GB1447474A (en) Indole-2-carbaldehydes
AU583831B2 (en) Monobasic diisobutamide derivatives
FR2418792A1 (fr) Derives de 3-azabicyclo(3.1.0)hexane, procede pour leur preparation, compositions biologiquement actives les contenant et procede herbicide les utilisant
ES8506011A1 (es) Procedimiento para la obtencion de un derivado de tetrahidrobenzotiazol
KR940008673A (ko) 살균조성물 및 이를 함유하는 비누
KR920002497A (ko) 스테롤 화합물
KR880006177A (ko) 구아니디노 메틸벤조산 유도체
KR880002844A (ko) 펜옥사지논, 이의 제조방법 및 용도
FR2382901A1 (ko)
FR2360560A1 (fr) Derives du d-threo-1-phenyl-2-trifluoracetamido-1,3-propane-diol et leurs applications en tant qu'antibiotiques
KR890005081A (ko) 제초효과가 있는 신규 2-옥시아미노알킬리덴-시클로헥산-1,3-디온 유도체
KR910012257A (ko) 벤즈안트라센 화합물 및 이의 제조방법
KR860007876A (ko) 제초제 조성물
KR860002498A (ko) 1,4-디하이드로피리딘 유도체의 약학조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee